US2003050461A1PendingUtilityA1

Secreted protein HFEAF41

53
Priority: Mar 21, 1997Filed: Oct 1, 2001Published: Mar 13, 2003
Est. expiryMar 21, 2017(expired)· nominal 20-yr term from priority
Inventors:Paul YoungJohn GreeneAnn FerrieSteven RubenCraig RosenRoxanne DuanJing-Shan HuKimberly FlorenceHenrik OlsenReinhard EbnerLauie BrewerPaul A. MooreYanggu ShiDavid LafleurJian Ni
A61P 9/12A61P 7/02A61P 9/10A61P 35/00A61P 35/02A61P 3/10A61P 37/04A61P 37/06A61P 7/06A61P 37/08A61P 25/28A61P 3/02A61P 29/00A61P 25/20A61P 25/18A61P 25/30A61P 3/04A61P 25/00A61P 25/16A61P 27/02A61P 19/02A61P 15/08A61P 17/00A61P 13/12A61P 17/02A61P 17/06G01N 33/6893A61K 38/00A61P 19/10A61P 21/04C07K 14/47C12Q 1/6883A61P 11/06A61P 15/16
53
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to 87 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . An isolated protein comprising amino acid residues 22 to 180 of SEQ ID NO:142.  
     
     
         2 . The isolated protein of  claim 1  which comprises amino acid residues 2 to 180 of SEQ ID NO:142.  
     
     
         3 . The isolated protein of  claim 1  which comprises amino acid residues 1 to 180 of SEQ ID NO:142.  
     
     
         4 . The protein of  claim 1  which comprises a heterologous polypeptide sequence.  
     
     
         5 . A composition comprising the protein of  claim 1  and a pharmaceutically acceptable carrier.  
     
     
         6 . An isolated protein produced by the method comprising: 
 (a) expressing the protein of  claim 1  by a cell: and    (b) recovering said protein.    
     
     
         7 . An isolated protein comprising the amino acid sequence of the secreted portion of the polypeptide encoded by the HFEAF41 cDNA contained in ATCC Deposit No. 97923.  
     
     
         8 . An isolated protein of  claim 7  which comprises the amino acid sequence of the complete polypeptide encoded by the HFEAF41 cDNA contained in ATCC Deposit No. 97923, excepting the N-terminal methionine.  
     
     
         9 . An isolated protein of  claim 7  which comprises the amino acid sequence of the complete polypeptide encoded by the HFEAF41 cDNA contained in ATCC Deposit No. 97923.  
     
     
         10 . The protein of  claim 7  which comprises a heterologous polypeptide sequence.  
     
     
         11 . A composition comprising the protein of  claim 7  and a pharmaceutically acceptable carrier.  
     
     
         12 . An isolated protein produced by the method comprising: 
 (a) expressing the protein of  claim 7  by a cell; and    (b) recovering said protein.    
     
     
         13 . An isolated protein comprising a polypeptide sequence which is at least 90% identical to amino acid residues 22 to 180 of SEQ ID NO:142.  
     
     
         14 . The isolated protein of  claim 13  wherein said polypeptide sequence is at least 90% identical to amino acid residues 1 to 180 of SEQ ID NO:142.  
     
     
         15 . The isolated protein of  claim 13  wherein said polypeptide sequence is at least 95% identical to amino acid residues 22 to 180 of SEQ ID NO:142.  
     
     
         16 . The isolated protein of  claim 13  wherein said polypeptide sequence is at least 95% identical to amino acid residues 1 to 180 of SEQ ID NO:142.  
     
     
         17 . The protein of  claim 13  which comprises a heterologous polypeptide sequence.  
     
     
         18 . A composition comprising the protein of  claim 13  and a pharmaceutically acceptable carrier.  
     
     
         19 . An isolated protein produced by the method comprising: 
 (a) expressing the protein of  claim 13  by a cell; and    (b) recovering said protein.    
     
     
         20 . An isolated protein comprising a polypeptide sequence which is at least 90% identical to the secreted portion of the polypeptide encoded by the HFEAF41 cDNA contained in ATCC Deposit No. 97923.  
     
     
         21 . The isolated protein of  claim 20  wherein said polypeptide sequence is at least 90% identical to the complete polypeptide encoded by the HFEAF41 cDNA contained in ATCC Deposit No. 97923.  
     
     
         22 . The isolated protein of  claim 20  wherein said polypeptide sequence is at least 95% identical to the secreted portion of the polypeptide encoded by the HFEAF41 cDNA contained in ATCC Deposit No. 97923.  
     
     
         23 . The isolated protein of  claim 20  wherein said polypeptide sequence is at least 95% identical to the complete polypeptide encoded by the HFEAF41 cDNA contained in ATCC Deposit No. 97923.  
     
     
         24 . The protein of  claim 20  which comprises a heterologous polypeptide sequence.  
     
     
         25 . A composition comprising the protein of  claim 20  and a pharmaceutically acceptable carrier.  
     
     
         26 . An isolated protein produced by the method comprising: 
 (a) expressing the protein of  claim 20  by a cell; and    (b) recovering said protein.    
     
     
         27 . An isolated protein comprising at least 30 contiguous amino acid residues of amino acid residues 22 to 180 of SEQ ID NO:142.  
     
     
         28 . The isolated protein of  claim 27  which comprises at least 50 contiguous amino acid residues of amino acid residues 22 to 180 of SEQ ID NO:142.  
     
     
         29 . The protein of  claim 27  which comprises a heterologous polypeptide sequence.  
     
     
         30 . A composition comprising the protein of  claim 27  and a pharmaceutically acceptable carrier.  
     
     
         31 . An isolated protein produced by the method comprising: 
 (a) expressing the protein of  claim 27  by a cell; and    (b) recovering said protein.    
     
     
         32 . An isolated protein comprising at least 30 contiguous amino acid residues of the secreted portion of the polypeptide encoded by the HFEAF41 cDNA contained in ATCC Deposit No. 97923.  
     
     
         33 . The isolated protein of  claim 32  which comprises at least 50 contiguous amino acid residues of the secreted portion of the polypeptide encoded by the HFEAF41 cDNA contained in ATCC Deposit No. 97923.  
     
     
         34 . The protein of  claim 33  which comprises a heterologous polypeptide sequence.  
     
     
         35 . A composition comprising the protein of  claim 33  and a pharmaceutically acceptable carrier.  
     
     
         36 . An isolated protein produced by the method comprising: 
 (a) expressing the protein of  claim 33  by a cell; and    (b) recovering said protein.    
     
     
         37 . An isolated protein comprising at least 30 contiguous amino acid residues of amino acid residues 1 to 180 of SEQ ID NO:142.  
     
     
         38 . The isolated protein of  claim 37  which comprises at least 50 contiguous amino acid residues of amino acid residues 1 to 180 of SEQ ID NO:142.  
     
     
         39 . The protein of  claim 37  which comprises a heterologous polypeptide sequence.  
     
     
         40 . A composition comprising the protein of  claim 37  and a pharmaceutically acceptable carrier.  
     
     
         41 . An isolated protein produced by the method comprising: 
 (a) expressing the protein of  claim 37  by a cell; and    (b) recovering said protein.    
     
     
         42 . An isolated protein comprising at least 30 contiguous amino acid residues of the complete polypeptide encoded by the HFEAF41 cDNA contained in ATCC Deposit No. 97923.  
     
     
         43 . The isolated protein of  claim 42  which comprises at least 50 contiguous amino acid residues of the complete polypeptide encoded by the HFEAF41 cDNA contained in ATCC Deposit No. 97923.  
     
     
         44 . The protein of  claim 42  which comprises a heterologous polypeptide sequence.  
     
     
         45 . A composition comprising the protein of  claim 42  and a pharmaceutically acceptable carrier.  
     
     
         46 . An isolated protein produced by the method comprising: 
 (a) expressing the protein of  claim 42  by a cell; and    (b) recovering said protein.

Join the waitlist — get patent alerts

Track US2003050461A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.